Hypercoagulability After Breast Cancer Surgery (EHC)

This study has been completed.
Information provided by:
Institut Bergonié
ClinicalTrials.gov Identifier:
First received: September 13, 2005
Last updated: July 25, 2013
Last verified: October 2007
The risk of deep venous thrombosis after radical breast surgery is known. The objective of this study is to explore hypercoagulability after radical breast cancer surgery by studying several factors for haemostasis before, during and after surgery. Ultrasound Doppler examination is realised between 24 and 72 hours post-operatively. Hypercoagulability is defined by a significant increasing level of thrombin-antithrombin, D-dimer and the endogen thrombin potential.

Condition Intervention
Breast Cancer
Blood Coagulation Disorders
Procedure: Blood collection (pre and postoperative): plasma coagulation parameters

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Plasma Coagulation Parameters and Hypercoagulability After Breast Cancer Surgery

Resource links provided by NLM:

Further study details as provided by Institut Bergonié:

Enrollment: 48
Study Start Date: January 2005
Study Completion Date: January 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Breast Cancer

Inclusion criteria:

  • Breast cancer
  • mastectomy

Exclusion criteria:

  • thrombophilia
  • anticoagulant treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00210197

Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France, 33076
Sponsors and Collaborators
Institut Bergonié
Principal Investigator: Youssef KABBANI, MD Institut Bergonié
  More Information

ClinicalTrials.gov Identifier: NCT00210197     History of Changes
Other Study ID Numbers: IB2005-06  EHC 
Study First Received: September 13, 2005
Last Updated: July 25, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut Bergonié:
Plasma coagulation parameters
Breast cancer

Additional relevant MeSH terms:
Blood Coagulation Disorders
Breast Neoplasms
Hemostatic Disorders
Breast Diseases
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Neoplasms by Site
Skin Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016